A detailed history of Headlands Technologies LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Headlands Technologies LLC holds 532 shares of FATE stock, worth $2,729. This represents 0.0% of its overall portfolio holdings.

Number of Shares
532
Holding current value
$2,729
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$3.54 - $8.35 $1,883 - $4,442
532 New
532 $3,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $498M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Headlands Technologies LLC Portfolio

Follow Headlands Technologies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Headlands Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Headlands Technologies LLC with notifications on news.